Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human CD20/MS4A1 Nanobody (SAA1332)

Catalog #:   RHC90701 Specific References (28) DATASHEET
Host species: Alpaca
Isotype: VHH-8His-Cys-tag
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RHC90701

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clonality

Monoclonal

Target

B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20

Concentration

1.12 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P11836

Applications

ELISA

Form

Liquid

Storage buffer

30mM Histidine, pH 5.8, 10% Sucrose, 0.06% Tween 80.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1332

Data Image
  • SDS-PAGE
    SDS PAGE for Human CD20/MS4A1 Nanobody
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910

Continuing progress in radioimmunotherapy for hematologic malignancies., PMID:39609167

CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of Anti-CD20 nanobody., PMID:38874667

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311

Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins., PMID:37899626

Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins., PMID:37552887

Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment., PMID:37055223

Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura., PMID:36757521

Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation., PMID:36631511

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells., PMID:36016223

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model., PMID:35499391

Advances in the management of TTP., PMID:35216839

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells., PMID:34429118

COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report., PMID:34327693

[Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura]., PMID:34248125

[Screening, expression and characterization of anti-human CD20 nanobodies]., PMID:33441230

Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody., PMID:33067738

Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly., PMID:32019116

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential., PMID:31931812

Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes., PMID:29922424

Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20., PMID:29574274

Nanobody Based Dual Specific CARs., PMID:29385713

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma., PMID:29054987

Thrombotic thrombocytopenic purpura., PMID:28416507

Selection and characterization of single domain antibodies against human CD20., PMID:27639717

Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas., PMID:23736700

Identification of novel tumor antigens with patient-derived immune-selected antibodies., PMID:18568347

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD20/MS4A1 Nanobody (SAA1332) [RHC90701]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only